taxane

(redirected from Taxanes)
Also found in: Medical.

tax·ane

 (tăk′sān′)
n.
Any of a class of anticancer drugs, such as paclitaxel, obtained from yew trees or synthesized, that inhibit the division of tumor cells by binding to and interfering with the action of microtubules.

[New Latin Tax(us), yew genus (from Latin taxus, yew) + -ane.]
References in periodicals archive ?
Currently available taxanes must be delivered intravenously, typically at an infusion center.
Intermittent docetaxel treatment offers patients the benefit of a "treatment holiday"--reducing their overall exposure to docetaxel and cumulative toxicity, and potentially delaying resistance to taxanes.
APP-111 is a platform technology that may have activity in other tumor types that have previously responded to taxanes or vinca alkaloids.
Thus, the use of the assay in breast cancer care will result in a more specific use of taxanes and a reduction of overtreatment thus avoiding serious side effects in patients and saving costs for the health care system.
In addition, PTX administered in the form of taxanes displayed much shorter MRT than PTX alone, and a possible explanation is that other taxane components may facilitate the transport of PTX out of the blood.
These include the taxanes (paclitaxel, docetaxel) and the vinca alkaloids (vincristine, vinblastine).
Taxanes (including paclitaxel and docetaxel) are the most widely used chemotherapy drug class in cancer medicine.
The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
Although mitosis-inhibiting drugs are used successfully to treat a range of cancers, only about 50 percent of ovarian cancer patients respond to taxanes and it is not yet possible to identify in advance which patients will benefit.
We shall discuss in this article the continuing saga of individual single gene predictors of sensitivity to anthracyclines and taxanes, followed by some of the 'multigene' predictors of recurrence risk in EBC.
The data clearly show that this small molecule, oral, targeted agent, in combination with capecitabine, is effective for women whose disease has progressed on previous therapies, including anthracyclines, taxanes and trastuzumab," said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GSK.